Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call
05 Mai 2022 - 1:30PM
Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading
pan-American (ex-USA) specialty pharmaceutical company, will
release its first quarter 2022 financial results on Thursday, May
12, 2022 prior to market opening. Following the release, Knight
will hold a conference call and audio webcast. Knight cordially
invites all interested parties to participate in this call.
Date: Thursday, May 12,
2022
Time: 8:30 a.m. ET
Telephone: Toll Free:
1-855-669-9657 or International 1-412-317-0790
Webcast:
www.gud-knight.com
or WebcastThis is a listen-only audio webcast.
Media Player is required to listen to the broadcast.
Replay: An archived replay will
be available for 30 days at
www.gud-knight.com.________________________________________
About Knight Therapeutics
Inc.
Knight Therapeutics Inc., headquartered in
Montreal, Canada, is a specialty pharmaceutical company focused on
acquiring or in-licensing and commercializing pharmaceutical
products for Canada and Latin America. Knight owns Biotoscana
Investments S.A., a pan-Latin American specialty pharmaceutical
company. Knight’s Latin American subsidiaries operate under United
Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics
Inc.'s shares trade on TSX under the symbol GUD. For more
information about Knight Therapeutics Inc., please visit the
company's web site at www.gud-knight.com or www.sedar.com.
Forward-Looking Statement
This document contains forward-looking
statements for Knight Therapeutics Inc. and its subsidiaries. These
forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ
materially from those contemplated by the forward-looking
statements. Knight Therapeutics Inc. considers the assumptions on
which these forward-looking statements are based to be reasonable
at the time they were prepared but cautions the reader that these
assumptions regarding future events, many of which are beyond the
control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could
cause actual results to differ materially from current expectations
are discussed in Knight Therapeutics Inc.'s Annual Report and in
Knight Therapeutics Inc.'s Annual Information Form for the year
ended December 31, 2021 as filed on www.sedar.com. Knight
Therapeutics Inc. disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information or future events, except as required by law.
Investor Contact: |
|
|
Knight Therapeutics Inc. |
|
|
Samira Sakhia |
|
Arvind Utchanah |
President & Chief Executive
Officer |
|
Chief Financial Officer |
T: 514.484.4483 |
|
T. +598.2626.2344 |
F: 514.481.4116 |
|
|
Email: info@knighttx.com |
|
Email: info@knighttx.com |
Website: www.gud-knight.com |
|
Website: www.gud-knight.com |
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
Von Apr 2023 bis Apr 2024